---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011474"
form_type: "8-K"
ticker: null
cik: "0001822711"
company_name: "PARDES BIOSCIENCES, INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:13:29.354283+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Pardes suspends pomotrelvir after Phase 2 miss; cuts 85% workforce; explores strategic alternatives

## Summary
- Phase 2 trial failed primary endpoint: 70% pomotrelvir vs 63% placebo undetectable virus at day 3 (p=0.57).
- Company suspends further clinical development of pomotrelvir.
- Board initiates review of strategic alternatives including acquisition or merger.
- Workforce reduced ~85% with estimated $5.7M cash restructuring costs in Q2 2023.
- Preliminary cash, equivalents and short-term investments ~$172.4M as of Mar 31, 2023.

## SEC filing metadata
- accession: 0000950170-23-011474
- form_type: 8-K
- cik: 0001822711
- company_name: PARDES BIOSCIENCES, INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822711/000095017023011474/0000950170-23-011474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822711/000095017023011474/prds-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011474
- JSON: https://secwatch.observer/filing/0000950170-23-011474.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011474.txt

## Key facts
- Restructurings & Charges
  PARDES BIOSCIENCES, INC. announced a restructuring with charges of $5.7 million affecting workforce (approximately 85%).
  - Type: restructuring
  - Charge: $5.7 million
  - Affected area: workforce
  - Headcount: approximately 85%
  source text: On March 31, 2023, the Board of Directors (the Board) of the Company approved a reduction in workforce (the Plan) to align operations with the changes in the Company’s corporate strategy. Under the Plan, due to the Company’s decision to suspend its clinical development of pomotrelvir and winddown its research and development activities, the Company is reducing headcount by approximately 85% through a reduction in its workforce. The Plan will take place in phases, with the first reduction in force occurring in April 2023, and is anticipated to be completed in the second quarter of 2023. The total cost related to the Plan is estimated to be approximately $5.7 million, all of which is cash-based expenditures related primarily to personnel expenses such as salaries, one-time severance payments and other benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000095017023011474/0000950170-23-011474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.